Display options
Cite
Wani RA, Dar MA, Chandel RK, et al. Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study. Neuropsychiatr Dis Treat. 2015;11:685-93doi: 10.2147/NDT.S80925.
Wani, R. A., Dar, M. A., Chandel, R. K., Rather, Y. H., Haq, I., Hussain, A., & Malla, A. A. (2015). Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study. Neuropsychiatric disease and treatment, 11685-93. https://doi.org/10.2147/NDT.S80925
Wani, Rayees Ahmad, et al. "Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study." Neuropsychiatric disease and treatment vol. 11 (2015): 685-93. doi: https://doi.org/10.2147/NDT.S80925
Wani RA, Dar MA, Chandel RK, Rather YH, Haq I, Hussain A, Malla AA. Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study. Neuropsychiatr Dis Treat. 2015 Mar 13;11:685-93. doi: 10.2147/NDT.S80925. eCollection 2015. PMID: 25792838; PMCID: PMC4364593.
Copy Download .nbib Format: NLM
Share it on

Neuropsychiatr Dis Treat. 2015 Mar 13;11:685-93. doi: 10.2147/NDT.S80925. eCollection 2015.

Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study.

Neuropsychiatric disease and treatment

Rayees Ahmad Wani, Mansoor Ahmad Dar, Rajesh Kumar Chandel, Yasir Hassan Rather, Inaamul Haq, Arshad Hussain, Altaf Ahmad Malla

Affiliations

  1. Department of Psychiatry, Government Medical College, Srinagar, Jammu and Kashmir, India.

PMID: 25792838 PMCID: PMC4364593 DOI: 10.2147/NDT.S80925

Abstract

BACKGROUND: Patients with schizophrenia suffer high rates of metabolic derangements on some antipsychotic medications that predispose them to cardiovascular diseases. Keeping this fact in mind, we planned this open-label study to see the effect on various metabolic parameters after switching stable schizophrenia subjects, who had developed metabolic syndrome on olanzapine, to aripiprazole.

METHODS: Sixty-two patients with schizophrenia who were stable on olanzapine and were fulfilling modified National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP-III) criteria for the presence of metabolic syndrome were enrolled on the study. Patients were randomly assigned either to switch to aripiprazole or to stay on olanzapine, on a 1:1 basis. Cross-tapering over a period of 1 month was done while switching patients to aripiprazole. Laboratory assessment for metabolic parameters was done at baseline, 8 weeks, and 24 weeks after enrollment; efficacy assessment was done using the Positive and Negative Syndrome Scale (PANSS) at baseline and 24 weeks, the Clinical Global Impressions severity subscale (CGI-S) at baseline, and the Clinical Global Impressions improvement subscale (CGI-I) at 24 weeks.

RESULTS: All parameters of metabolic syndrome (waist circumference, blood pressure, triglyceride level, fasting blood glucose, and high-density lipoprotein cholesterol) kept deteriorating in the stay group, compared with a continuous improvement in the switch group over time. At the end of the study, 26 patients (100%) from the stay group and 15 patients (42.8%) from switch group met the modified NCEP ATP-III criteria for presence of metabolic syndrome (P<0.001). There were no statistically significant differences between groups in psychopathology changes as measured by the PANSS total score and CGI-I scores.

CONCLUSION: Clinically stable patients with schizophrenia who are taking olanzapine and who have evidence of metabolic syndrome can be successfully switched to aripiprazole, with improvement in various parameters of metabolic syndrome and without any significant change in efficacy measures.

Keywords: aripiprazole; metabolic syndrome; olanzapine; schizophrenia; switching

References

  1. Ann Intern Med. 1993 Oct 1;119(7 Pt 2):655-60 - PubMed
  2. Drug Metab Pharmacokinet. 2005 Oct;20(5):368-78 - PubMed
  3. Psychopharmacology (Berl). 2013 Jul;228(2):175-85 - PubMed
  4. J Clin Psychiatry. 2008 Jul;69(7):1046-56 - PubMed
  5. J Clin Psychiatry. 1997;58 Suppl 10:45-9 - PubMed
  6. Am J Psychiatry. 2011 Sep;168(9):947-56 - PubMed
  7. Am J Psychiatry. 2008 Mar;165(3):352-8 - PubMed
  8. Schizophr Res. 2005 Dec 1;80(1):9-18 - PubMed
  9. Psychiatry Clin Neurosci. 2004 Feb;58(1):61-7 - PubMed
  10. Mol Psychiatry. 2008 Jan;13(1):27-35 - PubMed
  11. J Clin Psychiatry. 2001 Oct;62(10):757-71 - PubMed
  12. J Psychopharmacol. 2006 Jul;20(4 Suppl):15-8 - PubMed
  13. J Clin Psychiatry. 2006 Dec;67(12):1889-96 - PubMed
  14. J Clin Psychopharmacol. 2011 Oct;31(5):661-3 - PubMed
  15. J Clin Psychiatry. 2004;65 Suppl 18:47-56 - PubMed
  16. Int J Clin Pract. 2007 Dec;61(12 ):1960-2 - PubMed
  17. Drugs. 2004;64(15):1715-36 - PubMed
  18. Prim Care Diabetes. 2009 Feb;3(1):5-15 - PubMed
  19. Arch Gen Psychiatry. 2005 Jan;62(1):19-28 - PubMed
  20. Eur Neuropsychopharmacol. 2009 Aug;19(8):562-70 - PubMed
  21. Schizophr Bull. 2002;28(1):43-61 - PubMed
  22. Neuropsychopharmacology. 1999 May;20(5):491-505 - PubMed
  23. J Clin Psychiatry. 2003 Sep;64(9):1048-56 - PubMed
  24. Curr Med Res Opin. 2002;18(4):201-8 - PubMed
  25. JAMA. 2001 May 16;285(19):2486-97 - PubMed
  26. Diabetes Care. 2004 Feb;27(2):596-601 - PubMed
  27. Schizophr Res. 2003 Jun 1;61(2-3):123-36 - PubMed
  28. J Clin Psychiatry. 2007;68 Suppl 1:20-7 - PubMed
  29. Int J Neuropsychopharmacol. 2003 Dec;6(4):325-37 - PubMed
  30. J Clin Psychiatry. 2007;68 Suppl 6:14-23 - PubMed
  31. J Clin Psychiatry. 2010 Nov;71(11):1447-56 - PubMed
  32. N Engl J Med. 2005 Sep 22;353(12 ):1209-23 - PubMed
  33. Arch Gen Psychiatry. 2003 Jul;60(7):681-90 - PubMed
  34. J Intern Med Suppl. 1994;736:13-22 - PubMed
  35. Biol Psychiatry. 2009 Mar 15;65(6):510-7 - PubMed
  36. J Clin Psychopharmacol. 2013 Dec;33(6):740-6 - PubMed
  37. J Clin Psychiatry. 1998;59 Suppl 19:18-22 - PubMed
  38. J Clin Psychiatry. 2002 Sep;63(9):763-71 - PubMed
  39. Schizophr Res. 2008 Apr;101(1-3):273-86 - PubMed
  40. J Psychiatr Res. 1998 May-Aug;32(3-4):215-28 - PubMed
  41. CNS Drugs. 2005;19 Suppl 1:1-93 - PubMed
  42. Am J Psychiatry. 1999 Nov;156(11):1686-96 - PubMed
  43. Br J Psychiatry. 2006 Nov;189:433-40 - PubMed
  44. Atherosclerosis. 2006 Jun;186(2):367-73 - PubMed
  45. J Clin Psychiatry. 2002 Jun;63(6):516-23 - PubMed
  46. CNS Spectr. 2006 Jul;11(7 Suppl 7):32-9 - PubMed
  47. JAMA. 2002 Dec 4;288(21):2709-16 - PubMed
  48. J Clin Psychiatry. 2007 Jan;68(1):e02 - PubMed
  49. Schizophr Res. 2005 Dec 1;80(1):19-32 - PubMed
  50. Am J Psychiatry. 2006 Apr;163(4):611-22 - PubMed
  51. Psychopharmacology (Berl). 2002 Jun;162(1):3-10 - PubMed
  52. JAMA. 2008 Jan 9;299(2):185-93 - PubMed
  53. Psychopharmacology (Berl). 2006 Dec;189(2):259-66 - PubMed
  54. Schizophr Res. 2009 Jun;111(1-3):9-16 - PubMed
  55. Schizophr Bull. 1987;13(2):261-76 - PubMed
  56. Can J Psychiatry. 2006 Jul;51(8):480-91 - PubMed

Publication Types